Heron Therapeutics, Inc. (HRTX) News
Filter HRTX News Items
HRTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HRTX News Highlights
- For HRTX, its 30 day story count is now at 2.
- Over the past 4 days, the trend for HRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about HRTX are TOP.
Latest HRTX News From Around the Web
Below are the latest news stories about HERON THERAPEUTICS INC that investors may wish to consider to help them evaluate HRTX as an investment opportunity.
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime masterFor the first time in Hayao Miyazaki's decades-spanning career, the 82-year-old Japanese anime master is No. 1 at the North American box office. “The Boy and the Heron,” the long-awaited animated fantasy from the director of “Spirited Away,” “My Neighbor Totoro” and other cherished anime classics, is only the third anime to ever top the box office in U.S. and Canadian theaters, and the first original anime to do so. The film, which is playing in both subtitled and dubbed versions, is also the first fully foreign production to land atop the domestic box office this year. |
13 Hot Penny Stocks To Buy According to Hedge FundsIn this article, we will take a look at the 13 Hot Penny Stocks To Buy According to Hedge Funds. To see more hot penny stocks, go directly to 5 Hot Penny Stocks To Buy According to Hedge Funds. The overall market optimism helped by expectations that the Fed might start cutting interest rates in […] |
Penny Stock Powerhouses: 7 Picks Poised for Explosive GrowthUndeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. |
CEO & Director of Heron Therapeutics Craig Collard Buys 411% More SharesInvestors who take an interest in Heron Therapeutics, Inc. ( NASDAQ:HRTX ) should definitely note that the CEO... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! |
Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024Strategic Cost Reductions and Product Sales Growth Propel Optimism for Profitability |
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call TranscriptHeron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript November 14, 2023 Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.31. Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2023 Earnings Conference Call. As a reminder, this conference is being recorded. […] |
Q3 2023 Heron Therapeutics Inc Earnings CallQ3 2023 Heron Therapeutics Inc Earnings Call |
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesAlthough the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceHeron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2023 and highlighted recent corporate updates. |